Verge Labs Builds AI That Models Human Brain Disease From Blood Tests

Drug development for brain diseases fails at a staggering rate, and one core reason is that researchers often test therapies in the wrong patients. Verge Labs, a San Francisco AI company formerly known as Verge Genomics, is attempting to change that by building AI systems trained on the largest proprietary human brain dataset assembled to date — over 12,000 samples from thousands of patients, combined with genetic, molecular, and clinical records.

The company's flagship concept is the 'virtual biopsy.' Instead of requiring direct access to brain tissue, the AI integrates blood test results, imaging data, and clinical information to reconstruct a detailed molecular picture of what may be unfolding inside a patient's brain. This non-invasive approach could allow clinicians and researchers to stratify patients far earlier in the drug development process.

The strategic vision draws explicitly from precision oncology. Cancer medicine has shifted over the past two decades toward matching therapies to the specific biological characteristics of individual tumors. Neurology has not kept pace. Verge Labs is betting that sufficiently large and well-annotated human brain data, combined with modern AI architectures, can replicate that transformation for diseases like Alzheimer's, ALS, and Parkinson's.

Alongside its relaunch, Verge announced four senior hires from Altos Labs, Calico Life Sciences, Flatiron Health, and PostEra — organizations at the frontier of aging biology, computational medicine, and AI-driven drug discovery. CEO Alice Zhang framed the moment as the convergence of a decade of data collection with AI tools now capable of reasoning at the individual patient level.

For longevity-focused readers, the implications are significant but still early-stage. If virtual biopsy technology matures, it could accelerate trials for neuroprotective and neurorestorative therapies, potentially shortening the path from discovery to actionable interventions for age-related brain disease. Validation in prospective clinical studies remains the critical next step.